As part of our research program on the utilization of bioresouces in Thailand, we have been screening fungal extracts for in vitro assays inclusive of antimycobacterial and antiplasmodial activities. An extract from Aspergillus terreus BCC 4651 exhibited moderate activity against Mycobacterium tuberculosis H37Ra (minimum inhibitory concentration (MIC) 25 mg/ml) and the 1 H-NMR spectrum of the extract showed a unique profile, therefore, we selected the strain for large scale fermentation and chemical investigation. This study led to the isolation of two new butenolides, butyrolactones VI (1) and VII (2), together with the known compounds, butylolactone I (3), 1) butyrolactone II (4), 2) butyrolactone IV (5),
As part of our research program on the utilization of bioresouces in Thailand, we have been screening fungal extracts for in vitro assays inclusive of antimycobacterial and antiplasmodial activities. An extract from Aspergillus terreus BCC 4651 exhibited moderate activity against Mycobacterium tuberculosis H37Ra (minimum inhibitory concentration (MIC) 25 mg/ml) and the 1 H-NMR spectrum of the extract showed a unique profile, therefore, we selected the strain for large scale fermentation and chemical investigation. This study led to the isolation of two new butenolides, butyrolactones VI (1) and VII (2) , together with the known compounds, butylolactone I (3), 1) butyrolactone II (4), 2) butyrolactone IV (5), 3) butyrolactone V (6), 4) and aspernolide B (7). 5) A known diketopiperazine, bisdethiodi(methylthio)-acetylaranotin (8), [6] [7] [8] was also isolated as an antimycobacterial constituent of the culture extract. We report herein the structure elucidation of the new compounds and biological activities of isolated compounds.
Results and Discussion
Initial study of the cultures grown in a common liquid medium, Czapek-Dox broth, under shaking resulted in the isolation of the known compounds 3-5, 7, and 8. Further studies revealed that butyrolactone derivatives were efficiently produced when the fungus BCC 4651 was fermented in yeast extract sucrose medium (YES; a sucrose-rich liquid medium) under static conditions. The culture provided with two new compounds 1 and 2 along with 3, 5, 6 and terrein, which is one of the commonly occurring Aspergillus toxins. 9) These compounds were isolated by column chromatography (Sephadex LH-20, silica gel, and reversed-phase HPLC), wherein fractions were analyzed by TLC and 1 H-NMR. Compounds 3-5, and 7 were identified on the basis of the MS and NMR data as butyrolactone I, 1, 3) butyrolactone II, 2, 3) butyrolactone IV, 3) and aspernolide B, 5) respectively. All these butenolides were previously isolated from A. terreus. 2, 3, 5, 10, 11) 12) Methylation of 6 (MeI, K 2 CO 3 , N,N-dimethylformamide (DMF)) gave the dimethylated derivative 9, which was subsequently converted to the (S)-and (R)-a-methoxy-a-(trifluoromethyl)phenylacetic acid (MTPA) ester derivatives 10a and 10b, respectively. The Dd-values (d S -d R ) of the Mosher esters unambiguously indicated the 8ЉS-configuration (Fig. 1) .
Butyrolactone VI (1) was isolated as a colorless solid. The molecular formula was determined to be C 24 H 26 O 9 by high resolution-electrospray ionization-mass spectra (HR-ESI-MS). The IR spectrum showed broad and intense absorption bands at n max 3442 (broad) and 1739 cm 
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Rachada HARITAKUN, Pranee RACHTAWEE, Rungtiwa CHANTHAKET, Nattawut BOONYUEN, and Masahiko ISAKA* derivatives. The differences were observed at the prenylderived side chain (C-7Љ-C-11Љ (Fig. 2) . HMBC correlations from H 2 -7Љ to C-2Љ, C-3Љ, and C-4Љ, and from H-2Љ to C-7Љ indicated the connection of C-7Љ to C-3Љ. The structure of all other part of the molecule was identical to butyrolactone I (3), which was also confirmed on the basis of HMBC correlations (Fig. 2) . Although the resonances of hydroxyl protons (8Љ-OH and 9Љ-OH) were not observed, the carbon chemical shifts and the molecular formula (HR-MS) of this molecule required the diol structure of C-8Љ and C-9Љ. Thus, butyrolactone VI (1) is a new analogue wherein the double bond of the prenyl group in butyrolactone I (3) is dihydroxylated. The 13 C-NMR spectrum of 1 suggested the presence of a minor isomer, whose carbon resonances were mostly superimposed but some were separate from the major isomer with ca. 5 : 1 peak intensity ratio: C-5 (d C 38.4/38.3), C-5Љ (115.5/115.6), C-7Љ (33.6/33.7), C-8Љ (80.1/80.5), C-10Љ (24.8/25.0), and C-11Љ (24.2/24.1). These data indicated that the isolated compound (1) was a mixture of C-8Љ epimers. For the assignment of the C-8Љ absolute configuration of the major isomer by the modified Mosher's method, the same derivatization procedure as 6 was examined. However, treatment of 1 with MeI/K 2 CO 3 in DMF gave unexpectedly a complex mixture of products.
The molecular formula of butyrolactone VII (2) .5 (C-6) confirmed the location of the ethoxycarbonyl group. Therefore, 2 was assigned as the ethyl ester variant of butyrolactone I (3) .
The isolated compounds were tested for antimycobacterial activity against Mycobacterium tuberculosis H37Ra, antiplasmodial activity against the malarial parasite Plasmodium falciparum K1, and cytotoxicity to three human cancer cell-lines, KB (oral epidermoid carcinoma), MCF-7 (breast cancer) and NCI-H187 (small-cell lung cancer), and noncancerous Vero cells (African green monkey kidney fibroblasts) ( Table 1) . Compound 2 was not tested for these assays due to the sample limitation. Butyrolactones were weakly active or inactive against M. tuberculosis, whereas diketopiperazine 8 exhibited a significant growth inhibitory effect (MIC 1.56 mg/ml). On the other hand, butyrolactone V (6) showed moderate antimalarial activity (IC 50 7.9 mg/ml). Butyrolactone derivatives 1 and 3-7 exhibited very weak or no cytotoxicity. Butyrolactones I (3), II (4), III, and IV (5) are known to exhibit weak cytotoxicity to human cancer celllines, while they were inactive against several Gram-positive and Gram-negative bacteria.
3) Butyrolactone I (3) is also known to be a specific inhibitor of eukalyotic cyclin-dependent kinases.
13-15)

Experimental
General Experimental Procedures Melting points were measured with an Electrothermal IA9100 digital melting point apparatus. Optical rotations were measured with a JASCO P-1030 digital polarimeter. UV spectra were recorded on an Analytikjena SPEKOL 1200 spectrophotometer. Fourier transform-infrared (FT-IR) spectra were recorded on a Bruker VECTOR 22 spectrometer. NMR spectra were recorded on Bruker AV500D and DRX400 spectrometers. ESI-time-of-flight (TOF) mass spectra were measured with a Bruker micrOTOF mass spectrometer.
Fungal Material The fungus used in this study was isolated from a tree hole in Nam Nao National Park, Phetchabun Province, Thailand, by Dr. Wipapat Kladwang. This fungus was deposited in the BIOTEC Culture Col- .0 g, per liter), and final fermentation was carried out at 25°C for 20 d under static conditions. The cultures were filtered to separate broth (filtrate) and mycelia (residual cakes). The filtrate was extracted with EtOAc (4ϫ10 l) to give a brown gum (9.03 g, extract A). The wet mycelia were macerated in MeOH (2ϫ3 l, rt, 3 d) . The combined MeOH solution was partially concentrated by evaporation, diluted with H 2 O (100 ml), and defatted with hexane (300 ml). The residual solution was partially concentrated by evaporation, and extracted with EtOAc (3ϫ1.5 l) and concentrated under reduced pressure to obtain a brown gum (5.60 g, extract B). Extracts A and B were separately subjected to chromatographic fractionation. Extract A was fractionated by column chromatography (CC) on Sephadex LH-20 (4.6ϫ60 cm, MeOH) to obtain 8 pooled fractions A-1-A-8. Fraction A-4 (765 mg) was subjected to CC on silica gel (MeOH/CHCl 3 , step gradient elution from 0 : 100 to 100 : 0) followed by preparative HPLC using a reverse phase column (Phenomenex Luna 10u C18(2) 100A, 21.2 mmϫ250 mm; MeOH/H 2 Oϭ35 : 65, flow rate 8 ml/min) to furnish 6 (7.8 mg). Fraction A-5 (4.03 g) was repeatedly fractionated by CC on silica gel (MeOH/CHCl 3 ) to afford 3 (5.7 mg). Fraction A-6 (3.39 g) mostly composed of terrein. Extract B was fractionated by CC on Sephadex LH-20 (4.6ϫ60 cm, MeOH) to obtain 9 pooled fractions B-1-B-9. Fraction B-3 (830 mg) was subjected to CC on silica gel (3.0ϫ20 cm, MeOH/CH 2 Cl 2 , step gradient elution from 5 : 95 to 100 : 0) and preparative HPLC (MeOH/H 2 Oϭ40 : 60) to furnish 5 (5.7 mg), 2 (3.0 mg), and 3 (70.8 mg). Fraction B-4 (1.77 g) was separated by CC on silica gel (MeOH/CH 2 Cl 2 , step gradient elution) and preparative HPLC (MeOH/H 2 Oϭ40 : 60) to obtain 5 (422 mg), 6 (62.8 mg), and ergosterol (28.6 mg). Fractions B-5 (652 mg) and B-6 (736 mg) were combined and subjected to CC on silica gel (MeOH/CH 2 Cl 2 , step gradient elution) to afford 1 (161 mg).
Fermentation in Czapek-Dox Medium, Extraction, and Isolation The seed cultures of BCC 4651 in PDB were prepared in the same manner as described above. The final fermentation was performed using 20ϫ1000 ml Erlenmeyer flasks each containing 250 ml of Czapek-Dox broth (sucrose 30.0 g, NaNO 3 Biological Assays Growth inhibitory activity against Mycobacterium tuberculosis H37Ra and cytotoxicity to Vero cells were performed using the green fluorescent protein microplate assay (GFPMA). 16) Assay for activity against Plasmodium falciparum K1 (multi-drug resistant strain) was performed using the microculture radioisotope technique. 17) Cytotoxic activity against KB, MCF-7, and NCI-H187 cell-lines was evaluated using the resazurin microplate assay. 18) 
